COOPER COMPANIES, INC. DEF 14A Filing

Ticker: COO · Form: DEF 14A · Filed: Feb 2, 2024 · CIK: 711404

Complexity: moderate

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Executive Compensation, Cooper Companies, Ophthalmic Goods

TL;DR

<b>The Cooper Companies, Inc. filed its DEF 14A, detailing executive compensation and corporate governance for the period ending March 19, 2024.</b>

AI Summary

COOPER COMPANIES, INC. (COO) filed a Proxy Statement (DEF 14A) with the SEC on February 2, 2024. The filing is a Definitive Proxy Statement (DEF 14A) for The Cooper Companies, Inc. The report covers the period ending March 19, 2024, with a filing date of February 2, 2024. The company's fiscal year ends on October 31st. The company is incorporated in Delaware and its principal business is Ophthalmic Goods. The filing includes details on executive compensation, specifically stock awards and equity grants for both PEO (Principal Executive Officer) and Non-PEO members.

Why It Matters

For investors and stakeholders tracking COOPER COMPANIES, INC., this filing contains several important signals. This filing provides crucial information for shareholders regarding executive compensation packages, which can influence investment decisions and proxy voting. Understanding the details of equity awards and stock grants can offer insights into management's alignment with shareholder interests and the company's long-term strategy.

Risk Assessment

Risk Level: low — COOPER COMPANIES, INC. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance without immediate financial performance data.

Analyst Insight

Review the executive compensation details and equity award grants to assess management's incentives and alignment with shareholder value.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

When did COOPER COMPANIES, INC. file this DEF 14A?

COOPER COMPANIES, INC. filed this Proxy Statement (DEF 14A) with the SEC on February 2, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by COOPER COMPANIES, INC. (COO).

Where can I read the original DEF 14A filing from COOPER COMPANIES, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by COOPER COMPANIES, INC..

What are the key takeaways from COOPER COMPANIES, INC.'s DEF 14A?

COOPER COMPANIES, INC. filed this DEF 14A on February 2, 2024. Key takeaways: The filing is a Definitive Proxy Statement (DEF 14A) for The Cooper Companies, Inc.. The report covers the period ending March 19, 2024, with a filing date of February 2, 2024.. The company's fiscal year ends on October 31st..

Is COOPER COMPANIES, INC. a risky investment based on this filing?

Based on this DEF 14A, COOPER COMPANIES, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance without immediate financial performance data.

What should investors do after reading COOPER COMPANIES, INC.'s DEF 14A?

Review the executive compensation details and equity award grants to assess management's incentives and alignment with shareholder value. The overall sentiment from this filing is neutral.

How does COOPER COMPANIES, INC. compare to its industry peers?

The Cooper Companies, Inc. operates in the Ophthalmic Goods industry, which involves the manufacturing and distribution of products for eye care.

Are there regulatory concerns for COOPER COMPANIES, INC.?

This filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose information about executive compensation and other corporate matters.

Industry Context

The Cooper Companies, Inc. operates in the Ophthalmic Goods industry, which involves the manufacturing and distribution of products for eye care.

Regulatory Implications

This filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose information about executive compensation and other corporate matters.

What Investors Should Do

  1. Analyze the total compensation for named executive officers.
  2. Examine the details of stock awards granted, including vesting schedules and performance metrics.
  3. Review any proposals presented to shareholders for voting at the upcoming meeting.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document for executive compensation and corporate governance, not a financial performance report like an 8-K or 10-K.

Filing Stats: 4,310 words · 17 min read · ~14 pages · Grade level 14.2 · Accepted 2024-02-02 17:16:07

Filing Documents

EXECUTIVE COMPENSATION TABLES

EXECUTIVE COMPENSATION TABLES 45 Summary Compensation Table 45 Potential Payments Upon Termination or a Change in Control 50 CEO PAY RATIO 54 PAY VERSUS PERFORMANCE 54 PROPOSAL 1 — ELECTION OF DIRECTORS 61 PROPOSAL 2 — RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 69 PROPOSAL 3 — ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION 71 OTHER MATTERS 73 RECOMMENDATIONS 73 VOTING INFORMATION 73 STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR 77 RECONCILIATION OF NON-GAAP FINANCIAL MEASURES 78 2024 ANNUAL MEETING OF STOCKHOLDERS Date and Time: Tuesday, March 19, 2024, at 8:00 a.m. (Pacific Time) Location: 6101 Bollinger Canyon Road, Suite 500 San Ramon, California 94583 Notice Mailing Date: February 8, 2024 Record Date: January 24, 2024 This Proxy Statement is presented on our behalf by order of the Board of Directors (the "Board"). It contains information about our Company and the proposals to be presented at the Annual Meeting. Throughout this Proxy Statement we may also refer to various documents that are available on our website. The content posted on, or accessible through, our website is not incorporated by reference into this Proxy Statement or any of our filings with the U.S. Securities and Exchange Commission (the "SEC") and may be revised by us (in whole or in part) at any time, and from time to time. We have also furnished our 2023 Annual Report to all stockholders of record. The 2023 Annual Report contains our financial statements for the fiscal year ended October 31, 2023 and other useful information, but it is not part of the materials for the solicitation of proxies. _____________________________________________________________________________________________________________________________________________________________ Page 1 Proposals to Be Presented at the Annual Meeting PROPOSAL 1 – ELECTION OF DIRECTORS Page 61 Board Recommendation : FOR Each Director Vote Re

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing